Benign prostatic hyperplasia: current clinical practice.
Benign prostatic hyperplasia (BPH) is the most common benign adenoma in men, affecting nearly all of them. BPH represents a clinically significant cause of bladder outflow obstruction in up to 40% of men. The growing frequency of diagnosis is due to increasing life expectancy and a trend toward seeking medical advice at earlier stages of the disease. The last decade has witnessed a significant shift in emphasis in the management of BPH, with medical therapies and, to a lesser extent, minimally invasive therapies becoming the predominant active therapy choices. The development of effective therapies such as alpha-adrenergic blockers and 5-alpha-reductase inhibitors and the possibility of their combined use represent the most significant advance in the treatment of BPH.
Djavan
Bob
B
Department of Urology, New York University School of Medicine, New York University Hospital, 150 East 32nd Street, New York, NY 10016, USA. bdjavan@hotmail.com
Eckersberger
Elisabeth
E
Finkelstein
Julia
J
Espinosa
Geovanni
G
Sadri
Helen
H
Brandner
Roland
R
Shah
Ojas
O
Lepor
Herbert
H
D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D013196:Dihydrotestosterone / Q000378:metabolism; D018450:Disease Progression; D006801:Humans; D008297:Male; D011320:Primary Health Care; D011470:Prostatic Hyperplasia / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D011795:Surveys and Questionnaires; D013739:Testosterone / Q000378:metabolism; D057832:Watchful Waiting
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D018680:Cholinergic Antagonists; D013196:Dihydrotestosterone; D013739:Testosterone